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Abstract  
Pain is common in older adults, is frequently experienced as stressful, and is associated with 
increased morbidity and mortality. Stress regulatory systems are adaptive to challenge and 
change, allostasis, until demands exceed the adaptive capacity contributing to dysregulation, 
resulting in a high allostatic load. A high allostatic load is associated with increased risk of 
morbidity and mortality. Pain severity, based on the average intensity of frequent pain, was 
hypothesized to be positively associated with AL. Four formulations of AL were investigated. 
Cross-sectional data from Wave 4 (2008-2009) of the English Longitudinal Study of Aging 
(ELSA) were analysed. Covariates in the model included age, sex, education, smoking 
status, alcohol consumption, activity level, depression and common comorbid health 
conditions. A total of 5341 individuals were included; mean age 65.3(+9.2) years, 55% 
female, 62.4% infrequent or no pain, 12.6% mild pain, 19.1% moderate pain, and 5.9% 
severe pain. Severe pain was associated with greater AL defined by all four formulations. 
The amount of variance explained by pain severity and the covariates was highest when 
allostatic load was defined by the high risk quartile (12.9%) and by the clinical value (11.7%). 
Findings indicate a positive relationship between pain severity and AL. Further investigation 
is needed to determine if there is a specific AL signature for pain that differs from other 
health conditions.  
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Introduction  
     Up to 80% of adults aged 65 years and over report daily musculoskeletal pain [58,60] and 
21-43% report pain at two or more sites [19]. Ninety percent of all pain complaints in older 
people relate to the musculoskeletal system [60], and chronic musculoskeletal pain accounts 
for more than 12% of all consultations to primary care in people aged ≥ 50 years [17]. With 
the aging of the population and increased incidence of pain in older adults, identifying a 
measure that can reflect the physiological toll of pain could be beneficial for clinical research 
and patient care.  
     Allostasis is theoretical construct of the relationship between stress and physiological 
functioning. The body is designed to be adaptive to challenge and change. The cumulative 
experience of life including genetics, emotional and behavioral functioning, and life events 
can contribute toward a physiological toll or “wear and tear” known as allostatic load [37].  
When stress related systems: immune, metabolic, cardiovascular and neuroendocrine are 
persistently or extensively challenged without adequate recovery patterns of dysregulation 
become evident, indicating high allostatic load. It is important to note that extreme 
dysregulation in one system is not as likely to occur as subtle dysregulation across multiple 
systems, which is most predictive of negative health outcomes [22,51]. Allostatic load (AL) is 
evaluated by a composite measure that is empirically-supported, and is associated with and 
predictive of functional decline, disease, and death [18,21,49,52].   
     Pain is stressful. It is often perceived as aversive and threatening. As such it activates  
the stress response systems, and may contribute to an increased AL [6,23,47]. Consistent 
with the AL model, pain portends increased morbidity and mortality [2,9,29,33,61,62]. Altered 
immune, endocrine, and cardiovascular functioning has been demonstrated in individuals 
with persistent pain [15,27,43,46]. Psychosocial stress not only influences stress-system 
functioning, it is associated with increased risk for developing chronic pain [25,28,39] and 
exacerbating existing chronic pain conditions [26,43]. Aging is not only associated with 
increased experiences of chronic pain but also increased stress systems dysregulation 
[8,13,53]. Little is known about the consequences of pain on physiological functioning. A 
4 
 
significant and beneficial next step for research and patient care would be to understand and 
to measure the cumulative physiological toll of pain and aging on overall system functioning.  
     The relevance of measures of pain frequency, intensity, and duration on biological 
functioning is evident [3;13;24;29;30]. For example, dysregulated acute stress responses 
were demonstrated in individuals with chronic pain compared to those individuals with 
episodic pain [27]. Similarly, larger bilateral hippocampal volume and greater functional 
connectivity were found in individuals with low frequency chronic migraines compared to 
individuals with high frequency chronic migraines and healthy controls [30]. Consistent with 
the AL conceptualization, the experience of low frequency or episodic pain may facilitate an 
adaptive response and the experience of high frequency or persistent pain may promote 
physiological dysregulation and brain-related functional decline [37]. Nahin reported on pain 
prevalence and severity in a population-based study in the United States [38]. Based on a) 
pain persistence in the past three months and b) bothersomeness (little to a lot), one pain 
free and four pain severity categories  
(1-low to 4-high) were identified. Approximately 39.8 million individuals reported a level 3 or 
4 pain which was associated with worse health status and more disability compared to 
individuals with a level 1 or 2 of pain. As such it seems highly likely that the biological 
consequences of pain would differ across the groups. Although an initial investigation on the 
relationship between general definitions of pain and AL in a population based study reported 
supportive findings [57], further research evaluating the relationship between pain severity 
and AL is an important next step.  
     Another important consideration is that AL has been measured by a number of 
formulations with minimal differences found in predictive utility [18,51,53]. An AL sum score 
comprised of biological measures in the high risk quartile is the most frequently used 
measure. Other formulations include a standardized z-score, a lowest/highest 10%, and an 
index based on clinical ranges [18,53]. The formulation providing the greatest explanatory 
power and most associated with pain severity is unknown.  
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          The purpose of our study was to: 1) investigate the relationship between pain severity 
and AL, and 2) evaluate four formulations of AL and associated biomarkers and identify 
which explains the greatest variance in the association with pain severity. We hypothesized 
that a positive relationship between pain severity and AL would be demonstrated. 
Materials and Methods 
The English Longitudinal Study of Ageing (ELSA) is a nationally representative panel study of 
adults aged 50 years and over in England. The ELSA sample was drawn from households who 
participated in the Health Survey for England. Data on biomarkers was collected at Wave 4 (2008-
2009) and was used in this cross-sectional study. Although there were 10,336 participants who 
completed an interview in Wave 4, the analysis included only those with complete data on AL (i.e. 
collected during the nurse visit, n=5341). Compared to those subjects without complete AL data, 
those with complete AL data had obtained higher level of qualifications (p<0.001), were more likely 
to be a non-smoker (p<0.001), consume alcohol less frequently (p<0.001), were more active in 
vigorous (p>0.001), moderate (p<0.001) and mild activities (p<0.001) and less likely to be 
depressed (p<0.001) There was no difference for age (p=0.16) or sex (p=0.58). More detail on 
sampling and response rates for ELSA are provided elsewhere (Banks et al., 2010). All participants 
provided informed consent separately for the interview and nurse’s visit. Data were accessed 
through the Economic and Social Data Service. Ethical approval for the ELSA study was obtained 
from the London Multicentre Research and Ethics Committee. 
Allostatic load 
     Data on biomarkers were obtained during the nurse visit. Twelve biomarkers reflecting 
four systems (cardiovascular, immune, neuroendocrine, and metabolic) within the AL 
conceptualization were selected from the parent study and used to create an index of AL for 
this investigation [18,36]. Cardiovascular measures included systolic blood pressure, 
diastolic blood pressure, mean arterial pressure [54], and resting pulse rate. Immune 
measures included fibrinogen and C-reactive protein (CRP). Metabolic measures included 
high density lipoprotein (HDL), low density lipoprotein (LDL), glycosylated haemoglobin 
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(HBA1C), insulin-like growth factor-1 (IGF-1), and waist hip ratio (WHR). The 
neuroendocrine system was represented by Dehydroepiandrosterone (DHEAS),   
     To measure blood pressure, during the nurse visit, participants were seated and three readings 
of blood pressure were taken at one-minute intervals in the right arm using the OMRON HEM 907 
blood pressure monitor. Participants were asked not to smoke, consume alcohol, or exercise at 
least 30 minutes prior to taking the blood pressure reading and room temperature was adjusted to 
between 15°C and 25 °C. The mean of the last two readings for systolic and diastolic blood 
pressure were used for analysis and to calculate mean arterial pressure. Resting pulse was also 
obtained using the OMRON HEM 907 blood pressure monitor. Waist hip ratio was measured from 
measurement of waist and hip circumference using a tape measure.   
     All other biomarkers were obtained from a blood sample. Participants who had a clotting or 
bleeding disorder and those on anti-coagulant medication were not asked to provide blood 
samples. Unless participants were older than 80 years, had diabetes, reported ever having had a 
seizure, were frail or seemed unwell, the nurse collected fasting blood samples, which were 
deﬁned as not eating or drinking at least 5 h prior to the blood test. CRP was measured using the 
N Latex CRP mono immunoassay on the Behring Nephelometer II analyzer. Fibrinogen was 
analysed using a modiﬁcation of the Clauss thrombin clotting method on the Organon Teknika 
MDA 180 analyzer. Hemoglobin levels were measured with two Abbott Diagnostics Cell-Dyn 4000 
analysers. DHEAS measures were performed on the DPC Immulite 2000 analyser. IGF-1 
measures were analysed using IDS-iSYS immunoassay analyser. The assay represents a new 
generation of assay which is calibrated to the new WHO international standard for insulin-like 
Growth Factor-I, NIBSC code: 02/254.  The assay also conforms to the 2011 consensus statement 
on GH and IGF-I assays. Total cholesterol was analyzed using the cholesterol oxidase assay 
method and HDL cholesterol was analyzed using a direct method (no precipitation) on an Olympus 
640 analyzer [7]. Calculation of LDL using the Friedewald formula was performed and incorporates 
the measured total cholesterol value as follows: LDL = Total Cholesterol - HDL Cholesterol - 
Triglycerides / 2.2. All blood samples were analyzed at the Royal Victoria Infirmary laboratory in 
Newcastle upon Tyne, UK (see [7] for a detailed description of blood analyses). 
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     For this analysis four AL indices were created based on different methods for defining high risk 
for each biomarker. Table 2 provides a description for each formulation. Individuals with missing 
values for any biomarker were excluded from the analysis. Data on pain and putative confounders 
was collected using a standardised interview protocol. 
Pain severity 
     Similar to the pain severity coding system implemented by Nahin [38], pain severity was 
characterized in this study based on two questionnaire items: frequency of pain and intensity 
of pain. If individuals responded “yes” to “are you often troubled with pain?” they were then 
queried to rate “the intensity of their pain for most of the time” as mild, moderate, or severe. 
As such there were four categories in the current study determined by frequency of pain: no 
pain or infrequent pain, mild pain, moderate pain, and severe pain.  
Putative confounders 
     Age, sex, education, smoking status, frequency of alcohol consumption, activity levels, 
depression and health conditions common in older adults: cardiovascular disease, 
respiratory conditions, cancer, diabetes and arthritis were considered as putative 
confounders. Single items were used to measure all confounders other than depression. For 
educational attainment, participants were asked to specify their highest educational level and 
these were categorised as 1) a degree or equivalent; 2) higher education without a degree, 
National Vocational Qualification (NVQ) A level equivalent; 3) General Certificate of 
Secondary Education (GCSE); and 4) <GCSE, or 5) no qualification [3]. Past or present 
smoker status was determined by asking participants to indicate whether they 1) never 
smoked, 2) previously smoked or 3) currently smoke. Alcohol consumption was determined 
with a question about the frequency of alcohol consumption over the last 12 months. 
Responses were categorised as 1) ‘not at all’(referent), 2) ‘once or twice a year’, 3) once 
every two months’, 4) once or twice per week’, 5) three or four days a week’, 6) ‘five or six 
days a week,’ or 7) ‘every day’. Frequency of vigorous physical activity was measured as  
1) vigorous - more than twice a week (referent), 2) moderate - once or twice a week, and 3) 
mild - one to three times a month or hardly ever, were measured using single items. 
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Depression was measured using the eight item version of the Centre for Epidemiological 
Studies Depression (CES-D) scale [48]. Participants were asked to respond yes/no to eight 
questions regarding depressive symptoms experienced in the week prior to their ELSA 
interview. Responses were summed to give a score between 0 and 8 with a higher score 
indicating elevated depressive symptoms. Common health conditions in older adults (i.e. 
cardiovascular conditions, respiratory conditions, cancer, arthritis and diabetes) that may 
influence the relationship between pain severity and AL measures were assessed using 
single items that captured self-reported doctor-diagnosis (i.e. Has your doctor ever told you 
that you have had...).   
Analysis 
     First, the distribution of each putative confounder was examined by pain status with 
differences tested for significance using Chi-square or Kruskal Wallis tests where 
appropriate. Mean AL index scores, for all 4 definitions were calculated overall and by pain 
severity.  
     The distribution of the AL scores had minimal skewness and kurtosis (high and lowest 
25% skewness 0.44, kurtosis 2.66; 10th/90th percentile skewness 0.58, kurtosis 3.16; clinical 
values skewness 0.43, kurtosis 3.74; z-score skewness 0.63 kurtosis 3.44). To examine the 
association between pain severity and each of the four AL index scores linear regression 
was used. Initially, the association between pain severity and each AL formulation was 
adjusted for age, sex and educational attainment (Table 3: Model 1) and then cumulatively 
for all other confounders (i.e. age, sex, educational attainment, smoking status, frequency of 
alcohol consumption, frequency of mild, moderate and vigorous activity, depression, CVD, 
respiratory disease, cancer, diabetes and arthritis; Table 3: Model 2). Results for the 
allostatic load defined by high risk quartile, lowest/highest 10% and clinical values were 
expressed as unstandardized beta coefficients (B) with 95% confidence intervals. Results for 
the summary of allostatic load z-scores were expressed as standardized beta coefficients (β) 
with 95% confidence intervals.   
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     Additionally, logistic regression was used to examine the association between pain 
severity and high risk of allostatic load for each of the 12 biomarkers defined by high risk 
quartile, lowest/highest 10% and clinical values, adjusting for age, sex, education, CVD, 
respiratory disease, cancer, diabetes and arthritis. Results are expressed as adjusted odds 
ratios with 95% confidence intervals. Linear regression was used to examine the association 
between pain severity and the summary of z-scores for allostatic load biomarkers adjusting 
for the same confounders in the logistic regression. Stata version 13 was used for all 
analyses. For all analyses the “infrequent/no pain” group was classified as the referent 
category. R squared was used to estimate the % of total variation within each model of AL 
that was explained by pain and the confounders. 
Results 
Subject characteristics 
     The mean age among the 5341 participants was 65.3 (SD 9.2) years, 55.0% were 
women and 25% had no formal qualifications (Table 2). A total of 3331 (62.4%) subjects had 
infrequent or no pain, 675 (12.6%) had mild pain, 1019 (19.1%) had moderate pain and 316 
(5.9%) had severe pain. For moderate and severe pain, prevalence was higher in women 
(p<0.001). There was no relationship between pain severity and age.  
     The mean and standard deviation for the four allostatic load index scores are as follows: 
high risk quartile [3.2(2.0)], lowest/highest 10% [3.3(1.6)], clinical value [2.8(1.4)], and z-
scores [0.1(4.4)]. The mean allostatic index score increased with increasing pain severity for 
all definitions (Table 1).  
Association between pain severity and allostatic load index scores 
     After adjusting for age, sex and education, severe pain was associated with each of the 
four allostatic index scores (Table 3; Model 1). Mild pain was associated with allostatic load 
defined by the lowest/highest 10% (0.10; 0.01, 0.18). Moderate pain was associated with 
allostatic index score defined by the high risk quartile (unstandardized beta coefficient 0.15; 
95% confidence interval 0.08, 0.22) and clinical values (0.17; 0.07, 0.27) but not the 
lowest/highest 10% (0.07; -0.00, 0.14) or the summarised z-score (standardised beta 
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coefficient 0.19; 95% confidence interval -0.12, 0.50). The association between severe pain 
and each of the four allostatic load scores attenuated with adjustment for all confounders but 
remained significant (Table 3, Model 2). The associations for mild and moderate pain 
attenuated with the additional confounders to non-significance for all four definitions of 
allostatic load (Table 3, Model 2).   
      The relationship between covariates and increasing allostatic load differed by AL 
formulation (Model 2, supplemental data). Age was associated with increasing allostatic load 
score defined by high risk quartile and the summary of z-scores. Male sex was associated 
with increasing allostatic load score defined by high risk quartile, lowest/highest 10% and 
clinical values. Depression was only associated with increasing allostatic load defined by 
clinical values. Diabetes was associated with higher allostatic load index scores for all four 
formulations and cardiovascular disease was associated with three formulations. Arthritis 
and cancer were not associated with any formulation of allostatic load.  
Extent of variance of allostatic load explained by pain severity and covariates  
     The amount of variance explained by pain and the covariates was highest when allostatic 
load was defined by the high risk quartile (12.9%) and by the clinical value (11.7%), 
Supplemental Data. The amount of variance explained by pain and covariates when 
allostatic load was defined by the lowest/highest 10% and z-score were <5%.  
Association between pain severity and individual biomarkers 
     Additional analyses were completed to determine the association between pain severity 
and individual biomarkers. Adjusting for age, sex, education, and comorbid conditions, seven 
biomarkers were significantly associated with pain severity when high risk was defined by 
the high risk quartile (fibrinogen, HDL, CRP, HBA1c, DHEAS, IGF-1 and WHR), five when 
defined by clinical values (fibrinogen, HDL, CRP, HBA1c, and WHR), seven when high risk 
was defined by the lowest/highest 10% (resting pulse, fibrinogen, HDL, LDL, CRP, DHEAS, 
and IGF-1) and seven when defined by a z score (fibrinogen, HDL, LDL, CRP, HBA1c, 
DHEAS, WHR) (Table 4). Systolic blood pressure, diastolic blood pressure, and mean 
arterial pulse were not associated with pain severity.   
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Discussion   
     In line with the proposed hypotheses, two novel and important findings were generated 
from this study. First, consistent with the AL model, there was a positive relationship 
between pain severity and AL regardless of the formulation. Second, of the four 
formulations, the extent of variance explained by pain severity and covariates was greater 
with the high risk quartile and clinical values index than when defined by lowest/highest 10% 
and z score formulations. Our findings indicate that an AL composite may be able to capture 
the physiological toll of pain and associated biological, behavioral, and psychosocial factors 
on overall system functioning.     
Pain Severity and AL  
      Goertzel and colleagues reported a positive relationship between AL and pain intensity 
and frequency in adults with chronic fatigue syndrome [12]. In 2012, Slade and colleagues 
expanded on these findings demonstrating an association between AL and pain across three 
different categories in a population based study: severe headaches/migraines within three 
months, pain more than 24 hours within the previous month, and widespread bodily pain was 
reported [57]. Importantly, neurobiological findings emphasize the importance of considering 
frequency, intensity, and duration in the interpretation of biological changes in response to 
pain experiences. Nahin’s work further endorses these implications [38]. Pain severity was 
measured in community dwelling adults and based on two criteria: persistence (or frequency 
of pain) and the “bothersomeness” of pain. Adults with greater pain severity reported greater 
disability, worse health status, and more health care usage compared to those with less pain 
severity [38]. We extend previous findings by applying a similar definition of pain severity in a 
large population-based study of older adults and demonstrate that adults with greater pain 
severity also show a greater biological burden as indicated by a greater allostatic load.   
As such, our findings align with pain-related neurobiological changes reported [5,30,31] and 
extend previous findings by demonstrating the importance of considering pain severity, 
specifically frequency and intensity, when evaluating the biological interface of pain and 
associated biological, behavioural, and psychosocial stressors.  
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     Age is associated with an increasing AL resulting from decreasing physiological reserves 
[8,53]. The clinical ranges applied in the development of the clinical value index varied by 
age, thus, age differences were addressed within the formulation. An increase in AL with age 
was demonstrated in the high risk quartile and the z score formulation but not the 
highest/lowest 10% index formulations. Sex differences in pain [11] and biological measures 
[64] were indicated in our findings. Women had a greater prevalence of pain across 
moderate and severe categories and demonstrated a lower AL on three of four formulations.  
     Mood disturbances are frequently associated with chronic pain. In this study, symptoms 
of depression over the past week were measured, associations with AL were limited to the 
clinical value formulation. Findings are not surprising; a short-term measure of depressive 
symptoms would not be expected to be associated with physiological dysregulation. 
Symptoms of depression over the previous week would not differentiate acute transient 
symptoms of depression from those meeting a threshold of Major Depressive Disorder, if 
recurrent, may be of the intensity, persistence, and duration that could contribute to 
maladaptive biological changes.  
     Pain can be a consequence of and contribute to other morbidities. The inclusion of 
comorbid conditions in the fully adjusted model resulted in an attenuation of some AL 
associations and strengthening of others.  A diagnosis of cardiovascular disease and/or 
diabetes was positively associated with AL while cancer and/or arthritis were not. The 
resulting pattern may be related to the biomarkers included in the AL composite. However, 
there is significant variability in the stage of the health condition and associated contributions 
to biological functioning. Importantly, the AL formulations appear to be sensitive to the pain 
severity that extends through these various comorbid conditions, consistent with other recent 
findings [56].  Additionally, as noted in the methods, some blood samples were collected 
from non-fasting participants. We explored the possible influences of non-fasting samples, 
adjusting all analyses for fasting. There were no differences in the associations between 
pain severity and AL and pain severity and individual biomarkers.  Further, excluding non-
fasting participants from the analyses resulted in minimal changes. Thus, even after 
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controlling for conditions that can contribute to biological measure variance, the evidence 
remains that pain severity is associated with all formulations of AL. 
AL formulations  
     The merits and limitations of different AL formulations have been investigated and 
reviewed [18].  Regardless of the formulation, a multisystem approach has demonstrated 
better predictive utility compared to formulations with fewer systems represented [20,51,52]. 
In this study, the high risk quartile index was the strongest model with the clinical value index 
a close second. The associations between these formulations and age and sex were in the 
anticipated direction, providing further evidence of construct validity. Based on sample 
distribution, the high risk quartile is useful with large population-based studies [57], however, 
clinical application and utility in smaller studies is limited. Similar in the extent of variation in 
AL score explained, the clinical value index is based on population norms and reported 
ranges. Thus, the index is generalizable, accommodates age and sex differences, and can 
be implemented clinically. Two formulations were lower in the extent of variance explained: 
the lowest/highest 10% index and the z score formulation. The lowest/highest 10% index 
might be more applicable if specific clinical ranges were used for the values rather than a 
10% cut-off of the highest and lowest sample values. In regard to the z score formulation, 
the overall value is difficult to interpret, did not outperform other formulations, and would be 
difficult to implement clinically.   
Individual biomarkers 
     Questions have been raised as to whether the AL index should be comprised of a 
standard set of biomarkers by system (immune, cardiovascular, neuroendocrine, metabolic) 
or whether the biomarkers incorporated in an index should vary by condition [4,55]. 
Determining which biological measures are associated with pain severity is important, 
investigations specific to pain and AL and the biological measures which best capture that 
relationship are minimal [55,57].  
     The study included a comprehensive array of biomarkers from multiple systems [18,36]. 
Six biomarkers were repeatedly indicated as associated with pain severity in the fully 
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adjusted models. Fibrinogen, CRP, and HDL were significant in all four formulations and 
three additional biomarkers were associated with pain severity in three of the four 
formulations:  HbA1c, DHEAS, and WHR. DHEAS is an androgen with numerous benefits to 
include functioning as a HPA-axis antagonist, suppressing inflammatory cytokines, 
promoting lean muscle mass, among others [18]. Fibrinogen is a biomarker not typically 
referenced in pain research, it is a measure of inflammation and frequently identified as an 
indicator of cardiovascular disease risk. CRP is also a measure of inflammation and is 
associated with cardiovascular disease risk and cancer but unlike fibrinogen, CRP has been 
investigated in pain research and is associated with experimental pain, chronic pain, and 
functional disability [1,14,59]. Findings regarding HBA1c are interesting, even after 
controlling for diabetes, the associations with pain severity remained strong.  HDL is a 
measure reflective of metabolic functioning. High levels of HDL are protective. Thus, low 
levels are identified as a risk factor. WHR is a measure of adipose fat distribution, frequently 
conceptualized as a metabolic measure, high levels of WHR contribute to AL. 
     Interestingly, Slade and colleagues (2012) reported CRP, triglycerides, and BMI were 
strongly associated with pain across three categories and HBA1c, serum albumin and 
urinary creatinine with two. In a study of symptoms of chronic fatigue syndrome and 
allostatic load, CRP was the best predictor of bodily pain, based on the Medical Outcome 
Study 36-item Short Form Health Survey [12]. Noteworthy, the cardiovascular measures  
(systolic blood pressure, diastolic blood pressure, resting pulse, and mean arterial pulse), 
were not associated with pain severity. Olsen and colleagues reported that cardiovascular 
stress responsiveness was minimally associated with chronic pain in a large population-
based study [44]. The inclusion of cardiovascular measures in future allostatic load and pain 
studies requires further investigation. Although mean arterial pressure is highly correlated 
with systolic and diastolic blood pressure, there was some evidence of predictive utility [54] 
and it has been included in pain-related studies [44]. The findings do not support the 
inclusion of mean atrial pressures in future allostatic load formulations. Importantly, results 
are encouraging and highlight biomarkers to consider in future investigations.  
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Strengths, Limitations, and Future Directions 
     There are a number of strengths in the study design. ELSA is a large and well-
characterized sample of older adults living in England. Established study protocols ensure 
high quality data is available. In this analysis we have adjusted the relationship between pain 
and AL for relevant putative confounders at each stage. Consistent with prior studies, age, 
sex, and education were included in the adjusted model as well as adaptive and maladaptive 
behaviours such as smoking, alcohol use, and physical activity. We also considered 
confounding by comorbid conditions: cardiovascular and respiratory diseases, cancer, 
arthritis, and diabetes on the biomarkers included in the formulations. By doing so, we also 
control for medications associated with the treatment of those conditions [20].   
     There are also limitations for consideration. First, our analysis was limited to those 
individuals with complete allostatic load data. Second, the AL index is a measure to capture 
signs of physiological dysregulation due to challenges exceeding adaptive capacity over 
time. As such, quantifying the burden of a challenge is essential. The pain groups are not 
differentiated by duration or extent of pain. Additional measures (e.g. extent, duration) to 
characterize pain experiences may help differentiate level of stress-system burden. Third, 
pain severity and the covariates explained the greatest variance in the high risk quartile 
(12.9%) and the clinical value (11.7%) AL formulations. Hence, approximately 87% of the 
variance in the model remains unaccounted for. Additional measures to characterize pain 
burden may increase strength of the model in addition to inclusion of other measures such 
as sleep quality [34]. Fourth, this study is cross-sectional, a prospective investigation is an 
important next step. Fifth, inclusion of additional stress-related biological measures may 
provide an improved understanding of biological system functioning. Sixth, sex was included 
as a covariate in this study, future investigations would benefit by evaluation of the possible 
effect modification of sex. Additionally, the relationship between stress and health is adaptive 
with high AL indicated as a result of persistent, prolonged, and excessive stress, an 
important consideration when evaluating biomarkers and interpreting statistical models 
[20,21,35,37]. Lastly, AL is demonstrating utility as an indicator of the biological interface of a 
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person’s life experience [18,36]. As such, the AL index may be most useful as a measure to 
reflect current multi-system functioning and to serve as a biomarker to evaluate the impact of 
various biopsychosocial and behavioral interventions [23]. 
Conclusions      
     This study provides an important next step in understanding the relationship between 
pain severity and physiological dysregulation in aging adults. There are three key findings in 
this study: 1) a positive relationship between pain severity and the AL was demonstrated 
across all four formulations; 2) the high risk quartile and the clinical values index explained 
the greatest variance with AL when included with putative confounders; and 3) six 
biomarkers were consistently associated with pain severity. Importantly, a pain-related AL 
index may serve as a useful clinical and research measure indicating dysregulated stress-
system functioning and evaluating the physiological benefits of clinical interventions. 
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Highlights 
• Chronic pain is common in older adults.  
• Pain is typically experienced as stressful and associated with increased morbidity and 
mortality. 
• A positive relationship was demonstrated between pain severity and a biological 
measure of cumulative stress, allostatic load in older adults.  
• Findings support the potential utility of an allostatic load measure to evaluate 
physiological functioning in individuals with frequent pain and monitor changes to clinical 
interventions. 
 
   
 
 
 
 Supplemental Data for Table 3  
 Association between allostatic load index scores and pain severity, unstandardized beta coefficients with 95% confidence intervals. 
Covariates  High risk quartile for each 
biomarker  
High risk for each biomarker 
if in lowest or highest 10% 
High risk for each biomarker 
based on clinical values 
Z-score Summary 
Sex Female 
 
Male 
 
Referent 
 
0.23  
(0.18, 0.28) 
Referent 
 
0.25 
 (0.20, 0.31) 
Referent 
 
0.14  
(0.09, 0.20) 
Referent 
 
0.13  
(0.07, 0.19) 
Referent 
 
0.75  
(0.67, 0.82) 
 
Referent 
 
0.82  
(0.74, 0.90) 
Referent 
 
0.05  
(-0.19, 0.29) 
 
Referent 
 
0.06  
(-0.20, 0.32) 
Age  0.02  
(0.02, 0.03) 
0.02  
(0.02, 0.02) 
0.01  
(0.00, 0.01) 
0.00  
(-0.00, 0.01) 
-0.02  
(-0.02, -0.01) 
-0.02 
 (-0.03, -0.02) 
0.06  
(0.05, 0.07) 
0.05  
(0.04, 0.07) 
 
Education  
 
-0.05  
(-0.06, 0.04) 
-0.03  
(-0.05, -0.02) 
-0.02  
(-0.03, -0.00) 
-0.01 
 (-0.02, 0.00) 
-0.04  
(-0.06, -0.03) 
-0.02  
(-0.04, -0.00) 
-0.09 
 (-0.14, -0.04) 
-0.07  
(-0.13, -0.01) 
 
Smoking None 
 
Previous 
 
 
Current 
 
- 
 
- 
Referent 
 
0.15  
(-0.06, 0.24) 
 
0.20  
(0.11, 0.29) 
 Referent 
 
0.10  
(0.00, 0.20) 
 
0.05  
(-0.04, 0.15) 
 Referent 
 
0.16  
(0.03, 0.29) 
 
0.26  
(0.14, 0.39) 
 Referent 
 
0.49 
(-0.06, 0.91) 
 
0.41  
(0.01, 0.81) 
 
Alcohol 
 
 
-  
0.03 
 (0.02, 0.04) 
  
-0.00 
 (-0.01, 0.02) 
  
0.01 
 (-0.01, 0.03) 
  
-0.08  
(-0.14, -0.02) 
 
Physical  
Activity 
                            
 
Mild 
 
  
-0.02  
(-0.06, 0.01) 
  
0.02  
(-0.02, 0.05) 
  
-0.04  
(-0.09, 0.01) 
  
-0.19  
(-0.35, -0.02) 
                   
 
Moderate - 0.05  
(0.02, 0.08) 
 0.03  
(-0.01, 0.06) 
 0.08  
(0.04, 0.13) 
 0.14 
 (0.00, 0.28) 
                    
Vigorous 
-  
0.04  
(0.02, 0.07) 
  
0.02  
(-0.01, 0.03) 
  
0.09  
(0.06, 0.12) 
  
0.15  
(0.05, 0.26) 
 
Depression 
 -  
0.02  
(-0.00, 0.04) 
  
0.02  
(-0.01, 0.04) 
  
0.04  
(0.01, 0.07) 
  
0.06  
(-0.05, 0.16) 
   
 
 
 
 
Cardiovascular  
   
0.17  
(0.11, 0.24) 
  
0.08  
(0.02, 0.15) 
  
0.16  
(-0.18, 0.25) 
  
0.61  
(0.31, 0.91) 
 
Respiratory 
   
0.14  
(0.05, 0.24) 
  
-0.00  
(-0.10, 0.10) 
  
0.17  
(0.04, 0.31) 
  
0.73  
(0.32, 1.16) 
 
Cancer 
   
-0.05  
(-0.21, 0.10) 
  
0.03  
(-0.13, 0.19) 
  
0.03  
(-0.18, 0.25) 
  
-0.12  
(0.92, 0.58) 
 
Arthritis 
   
-0.02  
(0.08, 0.04) 
  
0.00  
(-0.06, 0.06) 
  
0.02  
(-0.07, 0.10) 
  
-0.21  
(-0.49, 0.06) 
 
Diabetes 
   
0.31  
(0.21, 0.42) 
  
0.50  
(0.40, 0.62) 
  
0.47  
(0.32, 0.62) 
  
0.86 
 (0.38, 1.34) 
 
R2 
 
  
0.094 
 
0.129 
 
0.014 
 
0.038 
 
0.078 
 
0.117 
 
0.026 
 
0.045 
Model 1:  Adjusted for age, gender and education 
Model 2:  Adjusted for age, gender, education, smoking status, frequency of alcohol consumption, mild, moderate, vigorous activity, depression, CVD,  
               respiratory disease, cancer, diabetes and arthritis 
 
Table 1. Description of Allostatic Load Formulations 
High Risk Quartile Lowest/Highest 10% Clinical Values Z Score 
 
The high risk AL index 
ranges from 0-12 [18]. 
 
Based on the sample data, 
quartile splits are 
computed. A point is given 
for each biomarker in the 
high risk range: 
 
 
Upper 25th risk quartile: 
 
Systolic BP 
 
Diastolic BP 
 
MAP 
 
Resting Pulse 
 
Fibrinogen 
 
CRP 
 
LDL 
 
Hb1AC 
 
Waist-Hip Ratio 
 
 
Lower 25th risk quartile: 
 
IGF1 
 
HDL 
 
DHEAS 
 
 
 
 
The lowest/highest 
AL index ranges from 
0-12.  
 
Based on the sample 
distribution, if an 
individual has a 
measure that is in  
the lower 10th or 
above the 90th 
percentile a score of 
1 is given [53]. 
 
 
 
The clinical values AL index 
ranges from 0-12.  
 
A sum is computed for each 
value considered out of normal 
clinical range: 
 
Systolic BP >140mmHg [41]  
 
Diastolic BP >90mmHg [41]  
 
MAP   <70 or >110 [16] 
 
Resting pulse< 60 or >100 
[42] 
  
Fibrinogen >4.0gL [24] 
 
HDL <1.03mol/L [10] 
 
LDL >4.1 mmol/L [10] 
 
CRP >3.0 [45] 
 
Hb1AC >6.5 [40]  
 
DHEAS  
men: > 65 years  
 <0.5umol/L and >5.6umol/L, 
aged 65 to 75 <0.3 umol/L   
and >6.7umol/L, aged 75+ 
<0.3umol/L and  >4.2umol/L;  
 
women: <65 years <1.4 umol/L 
and >8.0 umol/L,  between 65 
and 75 <0.9umol/L and 
>6.8umol/L and > 75 years  
<0.4umol/L & >5.3 umol/l [50] 
 
 IGF-1 - men <5 and >26    
    women <4 and >23 [32]  
             
 Waist-Hip Ratio  
 men >0.90, women >0.86 [63] 
 
 
The “Z-score” 
is a combined 
summary of the 
standardized 
scores for each 
biomarker 
based on 
sample 
distribution of 
biomarker 
values. 
 
  
 
Table 2: Participant characteristics overall and stratified by pain status (n=5341) 
 All 
 
(n=5341) 
 
No. (%) 
 
Infrequent/ 
No pain 
 
(n=3331) 
 
No. (%) 
 
Mild pain 
  
(n=675)  
 
No. (%) 
 
Moderate pain  
 
(n=1019) 
 
No. (%) 
 
Severe pain 
 
(n=316) 
 
No. (%) 
P-value 
Sex 
 
 
Male 
 
Female 
2403 (45.0) 
 
2938 (55.0) 
1608 (48.3) 
 
1723 (51.7) 
309 (45.8) 
 
366 (54.2) 
378 (37.1) 
 
641 (62.9) 
108 (34.2) 
 
208 (65.8) 
<0.001 
 
 
Age 
 
 
 
Mean (SD) 
 
65.3 (9.2) 
 
65.0 (9.2) 
 
64.0 (8.4) 
 
66.8 (9.5) 
 
66.2 (9.0) 
 
<0.001 
Education 
 
 
 
 
 
 
 
 
 
None 
 
< GCSE 
 
GCSE 
 
A-level 
 
< Degree 
 
Degree and 
above 
1293 (24.9) 
 
580 (11.2) 
 
1029 (19.8) 
 
444 (8.5) 
 
833 (16.0) 
 
1022 (19.7) 
672 (20.7) 
 
326 (10.1) 
 
660 (20.4) 
 
283 (8.7) 
 
556 (17.2) 
 
744 (23.0) 
146 (22.2) 
 
71 (10.7) 
 
134 (20.3) 
 
54 (8.2) 
 
124 (18.8) 
 
130 (19.7) 
340 (34.2) 
 
135 (13.6) 
 
189 (19.0) 
 
92 (9.3) 
 
119 (12.0) 
 
118 (11.9) 
135 (43.8) 
 
48 (15.6) 
 
46 (14.9) 
 
15 (4.9) 
 
34 (11.0) 
 
30 (9.7) 
<0.001 
 
Smoking 
 
 
Never 
 
Previous 
 
Current 
 
 
4114 (78.1) 
 
557 (10.5) 
 
606 (11.4) 
 
2640 (79.7) 
 
329 (9.9) 
 
343 (10.4) 
 
524 (78.4) 
 
79 (11.4) 
 
68 (10.2) 
 
757 (74.7) 
 
116 (11.5) 
 
140 (13.8) 
 
223 (71.0) 
 
36 (11.5) 
 
55 (17.5) 
 
<0.001 
Alcohol Everyday 800 (16.4) 534 (17.5) 97 (15.5) 137 (15.0) 32 (11.4) <0.001 
  
5-6 days 
per week 
 
 
730 (15.0) 
 
501 (16.4) 
 
100 (16.0) 
 
108 (11.8) 
 
21 (7.5) 
 
  
3-4 days 
per week 
 
 
1267 (26.0) 
 
 
816 (26.7) 
 
 
164 (26.2) 
 
 
229 (25.0) 
 
 
58 (20.7) 
 
  
1-2 times 
per week 
 
580 (11.9) 
 
366 (12.0) 
 
71 (11.4) 
 
115 (12.6) 
 
28 (10.0) 
 
  
Once every 
2 months 
 
335 (6.9) 
 
173 (5.7) 
 
54 (8.6) 
 
75 (8.2) 
 
33 (11.8) 
 
  
1-2 per 
year 
 
396 (8.1) 
 
213 (7.0) 
 
37 (5.9) 
 
110 (12.0) 
 
36 (12.9) 
 
  
Not at all 
 
438 (9.0) 
 
220 (7.2) 
 
53 (8.5) 
 
99 (10.8) 
 
66 (23.6) 
 
 
 
Allostatic Load  
Formulations 
 
 
 
 
High Risk 
Quartile 
 
 
Mean (SD) 
 
3.2 (2.0) 
 
Mean (SD) 
 
3.1 (2.0) 
 
Mean (SD) 
 
3.2 (2.0) 
 
Mean (SD) 
 
3.5 (2.0) 
 
Mean (SD) 
 
4.1 (2.0) 
 
 
 
<0.001 
 Highest/ 
Lowest 
10% 
3.3 (1.6) 3.3 (1.6) 3.4 (1.7) 3.4 (1.7) 3.7 (1.6) <0.001 
  
Clinical 
Values 
 
2.8 (1.4) 
 
2.7 (1.4) 
 
2.7 (1.4) 
 
2.8 (1.4) 
 
3.1 (1.4) 
 
<0.001 
  
Summary  
z-score 
 
 
-0.1 (4.4) 
 
-0.2 (4.3) 
 
-0.3 (4.3) 
 
0.2 (4.4) 
 
0.8 (4.7) 
 
<0.001 
 
 
   
 
 
 
 Table 3: Association between allostatic load index scores and pain severity, unstandardized beta coefficients with 95% confidence intervals. 
  High risk quartile for each 
biomarker  
High risk for each biomarker 
if in lowest or highest 10% 
High risk for each biomarker 
based on clinical values 
Z-score Summary 
Variable  Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
  B (95% CI) B(95% CI) B (95% CI) B (95% CI) B (95% CI) B (95% CI) B (95% CI) B (95% CI) 
Pain  None/Infrequent 
 
Mild 
 
 
Moderate  
 
 
Severe 
Referent 
 
0.08  
(-0.00, 0.16) 
 
0.15  
(0.08, 0.22) 
 
0.38  
(0.27, 0.49) 
Referent 
 
0.05  
(-0.04, 0.13) 
 
0.05 
 (-0.02, 0.13) 
 
0.24 
 (0.11, 0.36) 
Referent 
 
0.10 
 (0.01, 0.18) 
 
0.07  
(-0.00, 0.14) 
 
0.25  
(0.13, 0.37)) 
Referent 
 
0.08  
(-0.01, 0.16) 
 
0.01  
(-0.07, 0.09) 
 
0.16  
(0.03, 0.29) 
Referent 
 
-0.05  
(-0.06, 0.16) 
 
0.17  
(0.07, 0.27) 
 
0.49  
(0.33, 0.65) 
Referent 
 
0.0  
(-0.11, 0.12) 
 
0.03  
(-0.08, 0.14) 
 
0.26  
(0.08, 0.43) 
Referent 
 
-0.05  
(-0.41, 0.31) 
 
0.19  
(-0.12, 0.50) 
 
0.83  
(0.33, 1.34) 
Referent 
 
-0.10  
(-0.48, 0.28) 
 
0.01  
(-0.35, 0.34) 
 
0.59  
(0.02, 1.15) 
 
Model 1:  Adjusted for age, gender and education 
Model 2:  Adjusted for age, gender, education, smoking status, frequency of alcohol consumption, mild, moderate, vigorous activity, depression, CVD,  
               respiratory disease, cancer, diabetes and arthritis 
Significant associations are highlighted in bold. 
 
 
 
 
 
 
Table 4: Association between allostatic load individual biomarkers and pain severity 
 
Allostatic  Load 
Index Formulations 
 High Risk Quartile  Highest/Lowest 10% 
 High Risk 
Definition   
Mild pain 
OR (95% CI) 
Moderate pain 
OR (95% CI) 
Severe pain 
OR (95% CI) 
High Risk 
Definition   
Mild pain 
OR (95% CI) 
Moderate pain 
OR (95% CI) 
Severe pain 
OR (95% CI) 
Systolic blood 
pressure 
>143.5 0.92  
(0.75, 1.13) 
0.93 
 (0.78, 1.11) 
1.07 
 (0.81, 1.40) 
≤111.0 & 
≥155.5 
1.05  
(0.84, 1.31) 
0.96  
(0.79, 1.17) 
1.03  
(0.76, 1.40) 
 
 
Diastolic blood 
pressure 
 
>81.5 0.95  (0.78, 1.15) 
0.92 
 (0.77, 1.10) 
1.10 
 (0.83, 1.46) 
 
≤60.5 &  
≥88.5 
0.91  
(0.72, 1.13) 
0.97 
(0.80, 1.18) 
1.10 
(0.82, 1.47) 
 
Resting pulse 
 
 
 
>66.5 0.92  (0.74, 1.15) 
 
1.00 
 (0.84, 1.20) 
 
0.94 
 (0.71, 1.26) 
 
≤42  
& ≥78 
1.15 
(0.93, 1.43) 
1.06  
(0.88, 1.28) 
1.33  
(1.00, 1.77) 
Mean arterial 
pressure 
 
 
>101.0 0.94  (0.77, 1.14) 
0.99  
(0.83, 1.17) 
1.23 
 (0.94, 1.61) 
≤79  
& ≥109 
0.95 
 (0.76, 1.18) 
0.92  
(0.76, 1.12) 
1.17  
(0.88, 1.56) 
 
Fibrinogen 
 
 
>3.7 
 
1.06 
 (0.87, 1.28) 
 
1.03  
(0.88, 1.23) 
 
1.33 
 (1.03, 1.71) 
 
≤2.7  
& ≥4.1 
 
1.24  
(1.01, 1.52) 
 
1.07  
(0.89, 1.29) 
 
1.30  
(0.98, 1.73) 
 
HDL 
           
                   
     <1.4 
 
1.34 
 (1.11, 1.63) 
 
1.24  
(1.04, 1.48) 
 
1.75 
 (1.33, 2.29) 
 
≤1.1  
& ≥2.1 
 
1.14 
 (0.96,1.36) 
 
1.07  
(0.92, 1.25) 
 
1.44 
(1.12, 1.84) 
LDL 
 
>4.0 1.04 
(0.85, 1.26) 
0.99 
 (0.83, 1.18) 
 
0.96  
(0.72, 1.28) 
 
 
≤1.9 
& ≥4.6 
 
1.21  
(0.98, 1.49) 
 
1.08 
 (0.89, 1.30) 
 
1.40  
(1.06, 1.86) 
CRP >4.0 1.17  (0.96, 1.43) 
1.24 
 (1.05, 1.47) 
2.20 
 (1.71, 2.82) 
≤0.4  
& ≥7.9 
0.72 
(0.51, 1.03) 
0.71  
(0.52, 0.97) 
0.57 
(0.37, 0.89) 
 
Hb1AC 
 
>5.9 
 
1.13 
 (0.92, 1.39) 
 
1.21 
 (1.02, 1.45) 
 
1.48 
 (1.13, 1.95) 
 
≤5.3 
& ≥6.4 
 
1.11  
(0.89, 1.38) 
 
0.99  
(0.81, 1.21) 
 
1.14  
(0.83, 1.56) 
 
DHEAS 
 
<1.2 
 
1.13  
(0.92, 1.39) 
 
1.36 
 (1.15, 1.62) 
 
1.88 
 (1.43, 2.46) 
 
≤0.6 
& ≥4.7 
 
1.14 
 (0.92, 1.41) 
 
1.04 
 (0.87, 1.26) 
 
1.38  
(1.04, 1.83) 
 
IGF-1 
 
>12 
 
1.19 
 (0.97, 1.47) 
 
1.25 
 (1.04, 1.49) 
 
1.51  
(1.15, 1.98) 
 
≤9 
& ≥23 
 
1.03  
(0.84, 1.26) 
 
1.29  
(1.09, 1.53) 
 
   1.40  
    (1.07, 1.82) 
 
WHR 
 
<0.96 
 
1.21 
 (0.97, 1.52) 
 
1.39  
(1.14, 1.71) 
 
    1.45  
(1.03, 2.03) 
 
≤0.79  
& ≥1.01 
 
1.22  
(0.99, 1.51) 
 
1.07 
(0.89, 1.30) 
 
0.89 
 (0.65, 1.24) 
 
Allostatic Load 
Index Formulations 
 Clinical value  Z-score* 
 High Risk 
Definition 
Mild pain 
OR (95% CI) 
Moderate pain 
OR (95% CI) 
Severe pain 
OR (95% CI) 
Mild pain 
β (95% CI) 
Moderate pain 
β(95% CI) 
Severe pain 
β (95% CI) 
Systolic blood 
pressure 
>140 0.89  
(0.73, 1.08) 
1.05  
(0.89, 1.23) 
1.06  
(0.82, 1.38) 
-0.03 
(-0.11, 0.05) 
-0.01 
(-0.08, 0.06) 
0.08 
(-0.03, 0.19) 
 
Diastolic blood 
pressure 
 
>90 0.69  (0.48, 1.01) 
0.77 
 (0.56, 1.07) 
1.01  
(0.63, 1.62) 
 
-0.04 
(-0.12, 0.04) 
 
-0.05 
(-0.12, 0.02) 
 
0.03 
(-0.08, 0.14) 
 
Resting pulse 
 
 
 
<60 & 
>100 
1.06 (0.88, 
1.28) 
1.02  
(0.86, 1.20) 
 
0.98  
(0.75, 1.27) 
 
0.00 
(-0.07, 0.07) 
 
0.02 
(-0.04, 0.09) 
 
0.07 
(-0,03, 0.18) 
Mean arterial 
pressure 
 
<70 & 
>110 0.99  (0.73, 1.34) 
0.92 
 (0.70, 1.21) 
1.25  
(0.85, 1.85) 
-0.04 
(-0.12, 0.04) 
-0.04 
(-0.11, 0.04) 
0.06 
(-0.05, 0.17) 
 
Fibrinogen 
 
 
>4.0 1.18  (0.90, 1.56) 
1.13  
(0.89, 1.44) 
1.67 
 (1.20, 2.34) 
 
0.02 
(-0.06, 0.10) 
 
0.04 
(-0.04, 0.11) 
 
0.14 
(0.03, 0.26) 
 
HDL 
 
     
  <1.03 
 
1.19  
(0.86, 1.64) 
 
1.44 
 (1.10, 1.91) 
1.73 
 (1.14, 2.65) 
 
-0.12 
(-0.20, -0.05) 
 
-0.14 
(-0.21, -0.07) 
 
-0.24 
(-0.35, -0.13) 
LDL 
>4.1 1.03 
 (0.83, 1.27) 
 
0.92  
(0.75, 1.12) 
0.92  
(0.67, 1.26) 
 
-0.06 
(-0.14, -0.20) 
 
-0.05 
(-0.11, -0.02) 
 
-0.11 
(-0.22, -0.00) 
CRP 
>3.0 1.15 
 (0.96, 1.39) 
1.33 
 (1.13, 1.55) 
1.85 
 (1.45, 2.36) 
 
0.05 
(-0.03, 0.13) 
 
0.05 
(-0.02, 0.12) 
 
0.26 
(0.15, 0.38) 
 
Hb1AC 
 
>6.5 
 
1.22 
 (0.82, 1.83) 
1.03  
(0.73, 1.45) 
1.94  
(1.21, 3.12) 
 
0.09 
(0.02, 0.16) 
 
0.05 
 (-0.01, 0.10) 
 
0.16 
(0.07, 0.26) 
 
DHEAS 
 
Refer to 
text 
0.90 
 (0.72, 1.13) 
0.77 
 (0.63, 0.96) 
0.94  
(0.66, 1.32) 
 
0.04 
  (-0.04, 0.12) 
 
0.13 
(0.06, 0.20) 
 
  0.28 
    (0.17, 0.39) 
 
IGF-1 
 
Refer to 
text 
1.07  
(0.76, 1.49) 
1.22 
(0.91, 1.63) 
1.14  
(0.71, 1.83) 
 
-0.03 
  (-0.11, 0.06) 
 
0.02 
(-0.05, 0.09) 
 
   -0.04 
      (-0.16, 0.07) 
Waist-Hip ratio 
 
M >0.90  
W >0.86   
1.00  
(0.83, 1.22) 
1.25  
(1.06, 1.48) 
1.73 
(1.32, 2.27) 
 
0.06 
(-0.01, 0.13) 
 
0.10 
(0.03, 0.16) 
 
0.10 
(-0.00, 0.20) 
Note: Associations between biomarkers defined by highest quartile, highest and lowest 10% and clinical values and categories of pain severity are reported as 
adjusted odds ratios with 95% confidence intervals. Association between z-scores for biomarkers and pain are reported as standardised coefficients with 95% 
confidence intervals. The association between pain severity and each allostatic load score was adjusted for age, gender, education, CVD, respiratory disease, 
cancer, diabetes and arthritis. Significant associations are highlighted in bold. 
